Consistent with the ex vivo results, niraparib more notably inhibited the tumor with enhanced EXOSC1 (Figure 6G and I, and Figure 6—source data 1), indicating that EXOSC1 sensitized KIRC xenografts to the inhibitor. Here, EXOSC1 is linked to neoplasm.